Civitas’ Inhaled L-Dopa Candidate To Start Phase 1, Backed by Michael J. Fox Foundation Grant
This article was originally published in The Pink Sheet Daily
Executive Summary
Parkinson’s disease is crowded, but Civitas’ value proposition is attractive because the unmet need remains high, the technology shows promise, the clinical trials are straightforward and relatively rapid, and the company, a spinout of Alkermes, starts with clinically validated assets and infrastructure.